GlassScriptPhysician profile
Ashley Thrash
NPI 1578193389
$3,954.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,955.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $2,716.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.23 | 2021 | |
| Lilly USA, LLC | $170.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $162.38 | 2021 | |
| Novo Nordisk INC | $130.10 | 2021 | |
| Tandem Diabetes Care, INC. | $122.48 | 2021 | |
| Dexcom, INC. | $100.80 | 2021 | |
| Merck Sharp & Dohme LLC | $96.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $89.36 | 2021 | |
| Abbvie INC. | $30.54 | 2021 | |
| Ibsa Pharma INC. | $23.25 | 2021 | |
| Corcept Therapeutics | $20.84 | 2021 | |
| Medtronic, INC. | $17.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Thrash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.